Xu M, Yao C, Zhang W, Gao S, Zou H, Gao J. Int J Nanomedicine. 2021;16:27352749.
The authors have advised the Acknowledgment statement on page 2748 is incorrect. The acknowledgment section should read as follows:
The authors acknowledge the formulation for the docetaxel in Poly(2-oxazoline) micelles previously developed and published by the Kabanov lab with reference to Seo Y, Schulz A, Han Y, et al. Poly (2-oxazoline) block copolymer based formulations of taxanes: effect of copolymer and drug structure, concentration, and environmental factors. Polym Adv Technol. 2015;26(7):837850 (https://doi.org/10.1002/pat.3556).24 The current article reports the authors original research evaluating this polymeric micelle formulation of docetaxel in their own animal models. Dr Jing Gao wishes to acknowledge her time spent as a visiting scholar to the Kabanov lab at UNC-Chapel Hill from 2013-2014. This study was supported by Military Medical Innovation Project (16CXZ032), National Science and Technology Major Projects for Major New Drugs Innovation and Development (No. 2018ZX09J18107-003, 2018ZX0 9721003-005-009) and NSFC projects (No. 81773278, 81702491).
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Read more:
Corrigendum for the article Anti-Cancer Activity Based on the High Doc | IJN - Dove Medical Press
Recommendation and review posted by G. Smith
